Predictive Oncology Inc. Signs Letter of Intent to Acquire Quantitative Medicine (qtmed.com) and an AI EngineTM (CoRETM) that Facilitates Accelerated Drug Discovery and Development
(WorldNews Health)

PDF Version AI platform was developed at the Ray and Stephanie Lane Center for Computational Biology, which became the Computational Biology Department at Carnegie Mellon University and was successfully tested by several pharma companies MINNEAPOLIS, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (`Predictive Oncology` or `the Company`), a knowledge-driven company focused on applying artificial intelligence (`AI`) to personalized medicine and drug discovery, today announces it has signed a letter of intent to acquire Quantitative Medicine (QM). Dr. Carl Schwartz, president and CEO of Predictive Oncology, believes the synergies created by the acquisition, if...